Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002190 · ClinicalTrials.gov registry record · Phase 2
A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00002190: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00002190 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002190, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | Phase 2 |
What the finished NCT00002190 record still lists
NCT00002190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002190 about?
NCT00002190 is a clinical study titled "A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients". To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.
What is the current status of trial NCT00002190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants.
What interventions are being tested in trial NCT00002190?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002190?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002190's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer